Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical and investigative medicine. Medecine clinique et experimentale

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.25011/CIM.V37I4.21730PMID 25090264
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lancet

  2021cited by this paper
• Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.

  2014cited by this paper
• Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes

  2014cited by this paper
• Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome.

  2013cited by this paper
• Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• A matter of fat: insulin resistance and oxidative stress

  2012cited by this paper
• Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes

  2011cited by this paper
• Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

  2011cited by this paper
• Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study.

  2011cited by this paper
• Molecular structure of low density lipoprotein: current status and future challenges

  2009cited by this paper
• Small, dense LDL cholesterol and apolipoprotein B: relationship with serum lipids and LDL size.

  2009cited by this paper
• Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients.

  2009cited by this paper
• Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes

  2008cited by this paper
• Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

  2008cited by this paper
• Metformin therapy and clinical uses

  2008cited by this paper
• Metformin reduces cellular lysophosphatidylcholine and thereby may lower apolipoprotein B secretion in primary human hepatocytes.

  2008cited by this paper
• Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes *

  2008cited by this paper
• Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients.

  2007cited by this paper
• Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

  2006cited by this paper
• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

  2006cited by this paper
• Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

  2006cited by this paper
• Increased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study

  2005cited by this paper
• IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study.

  2004cited by this paper
• Insulin resistance increases circulating malondialdehyde-modified LDL and impairs endothelial function in healthy young men.

  2004cited by this paper
• Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.

  2003cited by this paper
• Increased Circulating Malondialdehyde-Modified LDL Levels in Patients With Coronary Artery Diseases and Their Association With Peak Sizes of LDL Particles

  2002cited by this paper
• Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL

  2002cited by this paper
• Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL.

  2001cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies.

  2000cited by this paper
• The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum.

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

  1998cited by this paper
• Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.

  1998cited by this paper
• Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterol

  1997cited by this paper
• Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.

  1994cited by this paper

• Dipeptidyl Peptidase-4 Inhibitors Improved Lipid Levels in Patients With Type 2 Diabetes: A Meta-analysis of Randomized Clinical Trials.

  2025cites this paper
• Effect of Metformin on Oxidative Stress and Left Ventricular Geometry in Nondiabetic Heart Failure Patients: A Randomized Controlled Trial

  2023cites this paper
• Effects of antidiabetic agents on Alzheimer’s disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin

  2022cites this paper
• A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function

  2019cites this paper
• Alendronate-induced gastric damage in normoglycemic and hyperglycemic rats is reversed by metformin.

  2019cites this paper
• Assessment of Clinical Aspects and Exhaled Breath Hydrogen Gas Originated from Intestinal Bacteria in Patients with Type 2 Diabetes

  2018cites this paper
• The regulatory role of DPP4 in atherosclerotic disease

  2017cites this paper
• Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients

  2017cites this paper
• Evaluation of carotid intima-media thickness with vascular endothelial growth factor and malondialdehyde levels in patients with sarcoidosis.

  2017cites this paper
• Role of Brown Fat in Lipoprotein Metabolism and Atherosclerosis.

  2016cites this paper
• No Deterioration of Blood Glucose and Arterial Stiffness by Switching Metformin to 500 mg Once Daily

  2015cites this paper
• Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis

  2015cites this paper